BindingDB logo
myBDB logout

71 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
12694187 9 Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors.BDB Uppsala University
15837308 19 Oximinoarylsulfonamides as potent HIV protease inhibitors.BDB Abbott Laboratories
8709110 27 Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design.BDB Agouron Pharmaceuticals, Inc.
8568831 42 Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.BDB Lilly Research Laboratories
8360874 19 Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands.BDB Merck Research Laboratories
16298527 10 Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.BDB University of Pennsylvania
16220977 9 Hydroxyethylene sulfones as a new scaffold to address aspartic proteases: design, synthesis, and structural characterization.BDB Philipps-Universitat Marburg
9871711 22 The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.BDB DuPont Merck Pharmaceutical Company
8667359 36 Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors.BDB DuPont Merck Pharmaceutical Company
9154969 20 Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.BDB DuPont Merck Pharmaceutical Company
15013001 10 Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.BDB GlaxoSmithKline
15533054 24 Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.BDB GlaxoSmithKline
15653343 20 Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'.BDB Uppsala University
9629473 34 Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site.BDB Sankyo Co. Ltd.
8879560 22 Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA--II. Modification of pyrrolidine ring at P1' proline.BDB Sankyo Co. Ltd.
10530956 45 Structure-activity relationship of HIV-1 protease inhibitors containing alpha-hydroxy-beta-amino acids. Detailed study of P1 site.BDB Sankyo Co. Ltd.
7724556 15 Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease.BDB Agouron Pharmaceuticals, Inc.
8709109 18 Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series.BDB Agouron Pharmaceuticals, Inc.
8894098 20 Discovery and optimization of nonpeptide HIV-1 protease inhibitors.BDB Parke-Davis Pharmaceutical Research
10465549 21 Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.BDB Parke-Davis Pharmaceutical Research
9371233 24 Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity.BDB Parke-Davis Pharmaceutical Research
7699705 19 Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.BDB Parke-Davis Pharmaceutical Research
10658583 50 Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.BDB Parke-Davis Pharmaceutical Research
7658450 20 Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.BDB Upjohn
9371244 59 4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease.BDB Parke-Davis Pharmaceutical Research
9836627 9 Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities.BDB DuPont Merck Pharmaceutical Company
9089336 77 Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.BDB Upjohn
9216835 30 Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.BDB Boehringer Ingelheim (Canada) Ltd.
8642565 36 Inhibitors of human immunodeficiency virus type 1 protease containing 2-aminobenzyl-substituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, activity, and oral bioavailability.BDB Sandoz Research Institute
8691434 25 Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.BDB Upjohn
9083477 11 Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.BDB Uppsala University
1588552 30 HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity.BDB Merck Research Laboratories
9719600 21 Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class.BDB Upjohn
8064795 29 A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs.BDB Parke-Davis Pharmaceutical Research
7932531 55 Inhibitors of HIV-1 proteinase containing 2-heterosubstituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, enzyme inhibition, and antiviral activity.BDB SANDOZ Forschungsinstitut Ges.m.b.H.
8021916 11 Aminodiol HIV protease inhibitors. 1. Design, synthesis, and preliminary SAR.BDB Bristol-Myers Squibb Company
8057276 11 Crystal-structure-based design and synthesis of novel C-terminal inhibitors of HIV protease.BDB Agouron Pharmaceuticals, Inc.
8295206 6 Design and synthesis of peptidomimetic inhibitors of HIV-1 protease and renin. Evidence for improved transport.BDB University of Pennsylvania
1588551 21 Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.BDB Merck Research Laboratories
2002466 13 Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors.BDB Merck Sharp and Dohme Research Laboratories
 25 Potent, orally bioavailable HIV-1 protease inhibitors containing noncoded D-amino acidsBDB Lilly Research Laboratories
8494379 4 In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.BDB National Cancer Institute
7783120 12 Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors.BDB Upjohn
7932546 5 Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors.BDB Upjohn
8544171 5 Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.BDB Upjohn
8171040 10 L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.BDB Merck Research Laboratories
8765512 25 Paracyclophanes: a novel class of water-soluble inhibitors of HIV proteinase.BDB Sandoz Research Institute
2002465 14 L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor.BDB Merck Research Laboratories
10737742 23 2',6'-Dimethylphenoxyacetyl: a new achiral high affinity P(3)-P(2) ligand for peptidomimetic-based HIV protease inhibitors.BDB Boehringer Ingelheim Pharmaceuticals Inc.
10346931 18 Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.BDB Japan Energy Corporation
11585445 10 Synthesis of potent C(2)-symmetric, diol-based hiv-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1' substituents.BDB Stockholm University
8642558 30 Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity.BDB Bristol-Myers Squibb Company
8230099 29 Synthesis and structure-activity relationships of a series of penicillin-derived HIV proteinase inhibitors containing a stereochemically unique peptide isostere.BDB Glaxo Group Research Ltd.
8230098 46 A series of penicillin derived C2-symmetric inhibitors of HIV-1 proteinase: synthesis, mode of interaction, and structure-activity relationships.BDB Glaxo Group Research Ltd.
11585446 6 Synthesis of novel, potent, diol-based HIV-1 protease inhibitors via intermolecular pinacol homocoupling of (2S)-2-benzyloxymethyl-4-phenylbutanal.BDB Stockholm University
8765511 14 Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.BDB University of Illinois at Chicago
8893827 17 Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.BDB Upjohn
8164260 23 The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors.BDB Merck Research Laboratories
8423599 26 Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere.BDB Monsanto Corporate Research
8423600 13 3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors.BDB Merck Research Laboratories
8464047 14 Cyclic sulfolanes as novel and high affinity P2 ligands for HIV-1 protease inhibitors.BDB Merck Research Laboratories
11543677 20 Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution.BDB Linkoping University
11170625 25 Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors.BDB Uppsala University
 7 SYNTHESIS AND PHARMACOKINETICS OF POTENT CARBAMATE HIV-1 PROTEASE INHIBITORS CONTAINING NOVEL HIGH AFFINITY HYDROXYETHYLAMINE ISOSTERESBDB Lilly Research Laboratories
 10 SYNTHESIS AND PHARMACOKINETICS OF POTENT CARBAMATE HIV-1 PROTEASE INHIBITORS CONTAINING NOVEL HIGH AFFINITY HYDROXYETHYLAMINE ISOSTERESBDB Lilly Research Laboratories
 9 Cycloalkylpiperazines as HIV-1 Protease Inhibitors: Enhanced Oral AbsorptionBDB Merck Research Laboratories
 10 Cycloalkylpiperazines as HIV-1 Protease Inhibitors: Enhanced Oral AbsorptionBDB Merck Research Laboratories
8759643 17 Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability.BDB Ciba-Geigy Ltd.
 8 INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C(2) SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE.BDB NCI-FCRDC
2200122 1 Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.BDB Abbott Laboratories
8558507 7 A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.BDB Abbott Laboratories